Rhino-Conjunctivitis - Pipeline Review, H1 2018

June 2018 | 76 pages | ID: R99B5DB5829EN
Global Markets Direct

Abstracts

Rhino-Conjunctivitis - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhino-Conjunctivitis - Pipeline Review, H1 2018, provides an overview of the Rhino-Conjunctivitis (Ophthalmology) pipeline landscape.

Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Phase II stages are 1, 9 and 8 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Rhino-Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Rhino-Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Rhino-Conjunctivitis (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Rhino-Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Rhino-Conjunctivitis - Overview
Rhino-Conjunctivitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Rhino-Conjunctivitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rhino-Conjunctivitis - Companies Involved in Therapeutics Development
ALK-Abello AS
Allergopharma GmbH & Co KG
Allergy Therapeutics Plc
ASIT Biotech SA
Astellas Pharma Inc
Bial - Portela & Ca SA
Faes Farma SA
HAL Allergy BV
Laboratorios LETI SL
Oxagen Ltd
Rhino-Conjunctivitis - Drug Profiles
Acaroid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Allergic Rhinitis and Rhino conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Birch Pollen Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhino conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Birch Pollen Induced Allergic Rhino conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for House Dust Mite Induced Allergic Rhinitis and Rhino conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhino conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhino conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergovac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-4070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bilastine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gp-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hdm-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pollinex Quattro Birch - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pollinex Quattro Grass - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Timapiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rhino-Conjunctivitis - Dormant Projects
Rhino-Conjunctivitis - Discontinued Products
Rhino-Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Feb 12, 2018: Completion of recruitment in PQ Grass Phase II trial
Jan 09, 2018: Allergy Therapeutics: PQ Birch Phase III clinical trial completes recruitment
Oct 19, 2017: Allergy Therapeutics: Commencement of dosing in PQ Grass Phase II Trial
May 30, 2017: ASIT biotech to disclose the detailed results of its phase III clinical study with gp-ASIT+ at EAACI 2017
Nov 30, 2015: Allergy Therapeutics Completes Patient Enrolment For Birch Study
May 18, 2014: BioTech Tools will be present at the EAACI congress
Jan 24, 2014: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet
Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultra short Grass Allergy Vaccine by Allergy Therapeutics
Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites
Jan 24, 2012: Faes Farma announces bilastine's launch in Brazil
Nov 28, 2011: Allergy Therapeutics Submits Complete Response to PEI In Germany And Clinical Study Protocol To FDA
Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study
Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain
Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries
Dec 02, 2010: Faes Farma: Bilastine is approved in eight European countries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Rhino-Conjunctivitis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Rhino-Conjunctivitis - Pipeline by ALK-Abello AS, H1 2018
Rhino-Conjunctivitis - Pipeline by Allergopharma GmbH & Co KG, H1 2018
Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics Plc, H1 2018
Rhino-Conjunctivitis - Pipeline by ASIT Biotech SA, H1 2018
Rhino-Conjunctivitis - Pipeline by Astellas Pharma Inc, H1 2018
Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca SA, H1 2018
Rhino-Conjunctivitis - Pipeline by Faes Farma SA, H1 2018
Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H1 2018
Rhino-Conjunctivitis - Pipeline by Laboratorios LETI SL, H1 2018
Rhino-Conjunctivitis - Pipeline by Oxagen Ltd, H1 2018
Rhino-Conjunctivitis - Dormant Projects, H1 2018
Rhino-Conjunctivitis - Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Rhino-Conjunctivitis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

ALK-Abello AS
Allergopharma GmbH & Co KG
Allergy Therapeutics Plc
ASIT Biotech SA
Astellas Pharma Inc
Bial - Portela & Ca SA
Faes Farma SA
HAL Allergy BV
Laboratorios LETI SL
Oxagen Ltd